|Mr. Kevin R. Sayer||Exec. Chairman, CEO & Pres||1.08M||1.64M||1958|
|Mr. Quentin S. Blackford||Exec. VP & CFO||N/A||N/A||1979|
|Mr. Steven R. Pacelli||Exec. VP of Strategy & Corp. Devel.||613.34k||317||1972|
|Mr. Andrew K. Balo||Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access||N/A||N/A||1948|
|Mr. Richard B. Doubleday||Exec. VP & Chief Commercial Officer||613.34k||N/A||1963|
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
DexCom, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 3; Compensation: 3.